


50-111-05

O I P Express Mail Label  
No. EV 453251505 US

SIU 7398  
PATENT



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Application of Kathleen C.M. Campbell  
Serial No. 10/694,448  
Filed October 27, 2003  
Confirmation No. 8896  
For THERAPEUTIC USE OF METHIONINE TO REDUCE THE TOXICITY OF  
PLATINUM-CONTAINING ANTI-TUMOR COMPOUNDS  
Examiner Rebecca Cook

Art Unit 1614

February 10, 2005

COMMISSIONER FOR PATENTS  
P.O. BOX 1450  
ALEXANDRIA, VIRGINIA 22313-1450

SIR:

**SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT**

In accordance with 37 C.F.R. 1.97 and 1.98 and MPEP 609, and in compliance  
with the duty of disclosure set forth in 37 C.F.R. 1.56, applicant submits the attached  
PTO/SB/08A for consideration by the Patent and Trademark Office in the above-  
entitled application and to be made of record therein.

\* Applicant submits herewith copies of the literature references.

\* A check in the amount of \$180.00 is enclosed to cover the fee specified in 37  
CFR §1.17(p) for submission of this Information Disclosure Statement.

Respectfully submitted,

A handwritten signature in black ink, appearing to read "Janet S. Hendrickson".

Janet S. Hendrickson, Ph.D., Reg. No. 55,258  
SENNIGER, POWERS  
One Metropolitan Square, 16th Floor  
St. Louis, Missouri 63102  
(314) 231-5400

JSH/dep

Mail Stop Amendment

PTO/SB/08A

**INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT**

(use as many sheets as necessary)



Sheet	1	of	1	Attorney Docket No.	SIU 7398
-------	---	----	---	---------------------	----------

**Complete if Known**

Application Number	10/694,448
Filing Date	October 27, 2003
Confirmation Number	8896
First Named Inventor	Kathleen C.M. Campbell
Group Art Unit	1614
Examiner Name	Rebecca Cook

**U.S. PATENT DOCUMENTS**

Examiner Initials*	Cite No. <sup>1</sup>	U.S. Patent Document		Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY
		Number	Kind Code <sup>2</sup> (if known)		

**FOREIGN PATENT DOCUMENTS**

Examiner Initials*	Cite No. <sup>1</sup>	Foreign Patent Document			Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	T <sup>6</sup>
		Office	Number <sup>4</sup>	Kind Code <sup>2</sup> (if known)			

**OTHER ART - NON PATENT LITERATURE DOCUMENTS**

Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>6</sup>
	76	AMMASH et al. "Inactivation of Aminoglycosides Against Pseudomonas aeruginosa by a Nutrition Supplementation Solution" Gen. Pharmac., Vol. 25, No. 3 (1994) pp. 461-466.	
	77	NEWMAN et al. "Inhibition of Biological Activity of Cisplatin by Thiourea and L-Methionine" J. of Clinical Hematology and Oncology, Vol. 9, No. 2 (1979) pp. 208-209.	

Examiner Signature	Date Considered
--------------------	-----------------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup>Unique citation designation number. <sup>2</sup>See attached Kinds of U.S. Patent Documents. <sup>3</sup>Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup>For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup>Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup>Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, D.C. 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, D.C. 20231.